Showing results (161-170 of 178) with videos related to

Sort By:
Pageof 18
The Lancet. Oncology|May 6, 2024
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 studyBob T Li, Funda Meric-Bernstam, Aditya Bardia, et al.
Gynecologic Oncology|January 11, 2024
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trialClaire F Friedman, Anishka D'Souza, Diana Bello Roufai, et al.
Cell Reports. Medicine|December 6, 2023
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trialJenna H Rannikko, Loic Verlingue, Maria de Miguel, et al.
Cancer Research Communications|February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid TumorsValentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2025
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancerByoung Chul Cho, Melissa Johnson, Jair Bar, et al.
Applied Clinical Informatics|September 11, 2024
Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer CentersCarlos Berenguer Albiñana, Matteo Pallocca, Hayley Fenton, et al.
Heart Rhythm|April 4, 2026
Improving Transthyretin cardiac amyloidosis detection from electrocardiograms through Willem AI platformEsther González-López, Ruben Abbou, Rafael López-García, et al.
The Lancet. Oncology|October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion studyChristina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Nature Medicine|July 13, 2026
An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trialMatteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, et al.
The New England Journal of Medicine|February 5, 2025
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive CancerAlison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Pageof 18